Overview - Asia-Pacific Markets for Dental Prosthetics and CAD CAM Devices 2010

Monday, February 8, 2010 Press Release J E 4
Asia-Pacific Markets for Dental Prosthetics and CAD CAM Devices 2010 In 2008 the Asia-Pacific market for dental prosthetics (crowns bridges and dentures) was valued at over US$6 billion. The Asia-Pacific market includes Australia Japan and South Korea. The aging population and greater demand for aesthetic dentistry are driving forces in the prosthetics market. The global economic crisis which began in 2008 has led to a slowdown in the overall market; however the market is expected to grow over the forecast period reaching US$7.2 billion by 2015. ( ) This market includes: Crowns and bridges Dentures Dental alloys and porcelain powder Computer aided design/computer aided manufacture (CAD/CAM) systems The Japanese market for dental prosthetics was the largest in terms of both unit volume and market value as it accounted for approximately 80% of the total Asia-Pacific market. All-ceramic prosthetic devices made using CAD/CAM technology are quickly gaining market share at the expense of conventionally fabricated devices. Although the economic recession has constrained patients’ discretionary incomes and limited the crowns and bridges market the market for all-ceramic restorations is expected to quickly re-establish growth following the economic recovery. The Asia-Pacific dental prosthetics market includes many local players such as: Addens Ceracys Dentaim and Renis in South Korea; GC in Japan; and Stoneglass in Australia. This report provides a comprehensive and detailed analysis of market revenues by device type market forecasts through 2015 unit sales average selling prices market drivers and limiters and a detailed competitive analysis including manufacturer market shares and product portfolios. To know more and to buy a copy of your report feel free to visit : Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: Website: Blog: Follow us on twitter:


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Novavax Terminates Negotiations with ROVI Pharmace...
Cell Therapeutics, Inc. (CTI) to Report Fourth Qua...